Aihua Tan1, Yiwu Dang2, Gang Chen2, Zengnan Mo3. 1. Department of Chemotherapy, The Affiliated Tumor Hospital of Guangxi Medical University Nanning 530021, Guangxi, China. 2. Department of Pathology, First Affiliated Hospital of Guangxi Medical University Nanning 530021, Guangxi, China. 3. Center for Genomic and Personalized Medicine, Guangxi Medical University Nanning 530021, Guangxi, China.
Abstract
BACKGROUND AND PURPOSE: Incidence of breast cancer is increasing and seems to be associated with fatty foods, metabolism, and so on. The fat mass and obesity associated gene (FTO) has been intensively investigated in diabetes, obesity and the other diseases. Previous studies have reported that FTO SNPs are associated with breast cancer risk. Here, we investigated the expression of FTO in human breast cancer tissues and its relationship with the clinicopathological features. METHODS: In this retrospective study, tissues from 79 patients with breast cancer were collected, as well as 43 cases of adjacent breast tissues. Immunohistochemistry was used to detect the expression of FTO. Statistical analysis was performed to assess the association between FTO expression and the clinicopathological features of breast cancer. RESULTS: FTO was expressed in both mammary epithelial and breast cancer tissues, but with different degree. The expression level of FTO in breast cancer tissues was significantly higher than that in the adjacent breast tissues (P < 0.001). The percentage of FTO-positive expression in cases with hormone receptor (HR) negative and HER2 amplification was significantly higher than that in those with HR positive and HER2 negative (P = 0.001, P < 0.001). The positivity rate of FTO in breast cancer with P53 positive and histological grade 3 seemed to be higher than that with P53 negative and histological grade 1 or 2, respectively (P = 0.077, P = 0.082). There was no association between FTO expression and age, T stage, LN status, TNM stage, Ki67, and BMI in breast cancer. Besides, FTO expression in HER2-overexpressed subtype was significantly higher than that in Triple-negative and Luminal A/B1 subtypes (P < 0.001). CONCLUSION: Our study suggests that FTO expression may have a vital role in the carcinogenesis of breast cancer, especially in HER2-overexpressed breast cancer.
BACKGROUND AND PURPOSE: Incidence of breast cancer is increasing and seems to be associated with fatty foods, metabolism, and so on. The fat mass and obesity associated gene (FTO) has been intensively investigated in diabetes, obesity and the other diseases. Previous studies have reported that FTO SNPs are associated with breast cancer risk. Here, we investigated the expression of FTO in humanbreast cancer tissues and its relationship with the clinicopathological features. METHODS: In this retrospective study, tissues from 79 patients with breast cancer were collected, as well as 43 cases of adjacent breast tissues. Immunohistochemistry was used to detect the expression of FTO. Statistical analysis was performed to assess the association between FTO expression and the clinicopathological features of breast cancer. RESULTS:FTO was expressed in both mammary epithelial and breast cancer tissues, but with different degree. The expression level of FTO in breast cancer tissues was significantly higher than that in the adjacent breast tissues (P < 0.001). The percentage of FTO-positive expression in cases with hormone receptor (HR) negative and HER2 amplification was significantly higher than that in those with HR positive and HER2 negative (P = 0.001, P < 0.001). The positivity rate of FTO in breast cancer with P53 positive and histological grade 3 seemed to be higher than that with P53 negative and histological grade 1 or 2, respectively (P = 0.077, P = 0.082). There was no association between FTO expression and age, T stage, LN status, TNM stage, Ki67, and BMI in breast cancer. Besides, FTO expression in HER2-overexpressed subtype was significantly higher than that in Triple-negative and Luminal A/B1 subtypes (P < 0.001). CONCLUSION: Our study suggests that FTO expression may have a vital role in the carcinogenesis of breast cancer, especially in HER2-overexpressed breast cancer.
Entities:
Keywords:
FTO expression; breast cancer; immunohistochemistry
Authors: Huixiang Li; Lurong Zhang; Hong Lou; Ivan Ding; Sunghee Kim; Luping Wang; Jiaoti Huang; P Anthony Di Sant'Agnese; Jun-Yi Lei Journal: Am J Clin Pathol Date: 2005-08 Impact factor: 2.493
Authors: Michelle Harvie; Anthony Howell; Robert A Vierkant; Nagi Kumar; James R Cerhan; Linda E Kelemen; Aaron R Folsom; Thomas A Sellers Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-03 Impact factor: 4.254
Authors: A Trentham-Dietz; P A Newcomb; B E Storer; M P Longnecker; J Baron; E R Greenberg; W C Willett Journal: Am J Epidemiol Date: 1997-06-01 Impact factor: 4.897
Authors: Z Huang; S E Hankinson; G A Colditz; M J Stampfer; D J Hunter; J E Manson; C H Hennekens; B Rosner; F E Speizer; W C Willett Journal: JAMA Date: 1997-11-05 Impact factor: 56.272
Authors: Julia Fischer; Linda Koch; Christian Emmerling; Jeanette Vierkotten; Thomas Peters; Jens C Brüning; Ulrich Rüther Journal: Nature Date: 2009-02-22 Impact factor: 49.962
Authors: Ross L Prentice; Bette Caan; Rowan T Chlebowski; Ruth Patterson; Lewis H Kuller; Judith K Ockene; Karen L Margolis; Marian C Limacher; JoAnn E Manson; Linda M Parker; Electra Paskett; Lawrence Phillips; John Robbins; Jacques E Rossouw; Gloria E Sarto; James M Shikany; Marcia L Stefanick; Cynthia A Thomson; Linda Van Horn; Mara Z Vitolins; Jean Wactawski-Wende; Robert B Wallace; Sylvia Wassertheil-Smoller; Evelyn Whitlock; Katsuhiko Yano; Lucile Adams-Campbell; Garnet L Anderson; Annlouise R Assaf; Shirley A A Beresford; Henry R Black; Robert L Brunner; Robert G Brzyski; Leslie Ford; Margery Gass; Jennifer Hays; David Heber; Gerardo Heiss; Susan L Hendrix; Judith Hsia; F Allan Hubbell; Rebecca D Jackson; Karen C Johnson; Jane Morley Kotchen; Andrea Z LaCroix; Dorothy S Lane; Robert D Langer; Norman L Lasser; Maureen M Henderson Journal: JAMA Date: 2006-02-08 Impact factor: 56.272
Authors: D C Allred; G M Clark; R Elledge; S A Fuqua; R W Brown; G C Chamness; C K Osborne; W L McGuire Journal: J Natl Cancer Inst Date: 1993-02-03 Impact factor: 13.506
Authors: Timothy M Frayling; Nicholas J Timpson; Michael N Weedon; Eleftheria Zeggini; Rachel M Freathy; Cecilia M Lindgren; John R B Perry; Katherine S Elliott; Hana Lango; Nigel W Rayner; Beverley Shields; Lorna W Harries; Jeffrey C Barrett; Sian Ellard; Christopher J Groves; Bridget Knight; Ann-Marie Patch; Andrew R Ness; Shah Ebrahim; Debbie A Lawlor; Susan M Ring; Yoav Ben-Shlomo; Marjo-Riitta Jarvelin; Ulla Sovio; Amanda J Bennett; David Melzer; Luigi Ferrucci; Ruth J F Loos; Inês Barroso; Nicholas J Wareham; Fredrik Karpe; Katharine R Owen; Lon R Cardon; Mark Walker; Graham A Hitman; Colin N A Palmer; Alex S F Doney; Andrew D Morris; George Davey Smith; Andrew T Hattersley; Mark I McCarthy Journal: Science Date: 2007-04-12 Impact factor: 47.728
Authors: Thomas Gerken; Christophe A Girard; Yi-Chun Loraine Tung; Celia J Webby; Vladimir Saudek; Kirsty S Hewitson; Giles S H Yeo; Michael A McDonough; Sharon Cunliffe; Luke A McNeill; Juris Galvanovskis; Patrik Rorsman; Peter Robins; Xavier Prieur; Anthony P Coll; Marcella Ma; Zorica Jovanovic; I Sadaf Farooqi; Barbara Sedgwick; Inês Barroso; Tomas Lindahl; Chris P Ponting; Frances M Ashcroft; Stephen O'Rahilly; Christopher J Schofield Journal: Science Date: 2007-11-08 Impact factor: 47.728
Authors: Michał Marcinkowski; Tomaš Pilžys; Damian Garbicz; Jan Piwowarski; Damian Mielecki; Grzegorz Nowaczyk; Michał Taube; Maciej Gielnik; Maciej Kozak; Maria Winiewska-Szajewska; Ewa Szołajska; Janusz Dębski; Agnieszka M Maciejewska; Kaja Przygońska; Karolina Ferenc; Elżbieta Grzesiuk; Jarosław Poznański Journal: Int J Mol Sci Date: 2021-04-26 Impact factor: 5.923